{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:14:06Z","timestamp":1778930046856,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Clinical outcomes in patients with early rheumatoid arthritis (RA) were assessed by baseline symptom duration in the Assessing Very Early Rheumatoid arthritis Treatment trial (ClinicalTrials.gov; NCT01142726). Patients with early, active RA were randomized to subcutaneous (SC) abatacept 125\u00a0mg\/week plus methotrexate (MTX), SC abatacept alone, or MTX monotherapy for 12 months. All RA treatments were withdrawn after 12 months in patients with Disease Activity Score in 28 joints (C-reactive protein; DAS28-CRP)\u2009&lt;\u20093.2. In this post hoc analysis, the proportion of patients achieving protocol-defined remission (DAS28-CRP\u2009&lt;\u20092.6) or improvement in physical function at 12 and at both 12 and 18 months was assessed according to symptom duration (\u2264\u20093 months, &gt;\u20093 to \u2264\u20096 months, or &gt;\u20096 months) and treatment group. No clinically significant differences were seen in baseline demographics or characteristics across symptom duration groups. Irrespective of baseline symptom duration, a numerically higher proportion of abatacept plus MTX-treated patients achieved DAS-defined remission at month 12 and sustained remission at month 18 compared with MTX monotherapy. A numerically higher proportion of abatacept plus MTX-treated patients with symptom duration\u2009\u2264\u20093 months maintained DAS-defined remission after complete treatment withdrawal from 12 to 18 months compared with longer symptom duration groups. This subgroup also had the fastest onset of clinical response (DAS28-CRP\u2009&lt;\u20092.6) after initiation of treatment. Health Assessment Questionnaire\u2013Disability Index response was similar regardless of baseline symptom duration. Overall, symptom duration of \u2264\u20093 months was associated with a faster onset of clinical response and higher rates of drug-free remission following treatment with abatacept plus MTX.<\/jats:p>","DOI":"10.1007\/s00296-018-4173-3","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T01:12:15Z","timestamp":1539997935000},"page":"2225-2231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1219-3845","authenticated-orcid":false,"given":"Vivian P.","family":"Bykerk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard G.","family":"Combe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"key":"4173_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.berh.2008.11.006","volume":"23","author":"B Combe","year":"2009","unstructured":"Combe B (2009) Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23:59\u201369","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4173_CR2","first-page":"1","volume":"80","author":"JJ Cush","year":"2007","unstructured":"Cush JJ (2007) Early rheumatoid arthritis\u2014is there a window of opportunity? J Rheumatol Suppl 80:1\u20137","journal-title":"J Rheumatol Suppl"},{"key":"4173_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"JJ Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43:22\u201329","journal-title":"Arthritis Rheum"},{"key":"4173_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510\u2013516","journal-title":"Ann Rheum Dis"},{"key":"4173_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, Karyekar CS, Wong DA, Huizinga TW (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19\u201326","journal-title":"Ann Rheum Dis"},{"key":"4173_CR6","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56:3226\u20133235","journal-title":"Arthritis Rheum"},{"key":"4173_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/annrheumdis-2014-206047","volume":"74","author":"JA van Nies","year":"2015","unstructured":"van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, AH vdH-vM (2015) Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74:806\u2013812","journal-title":"Ann Rheum Dis"},{"key":"4173_CR8","first-page":"494","volume":"29","author":"Y Yazici","year":"2011","unstructured":"Yazici Y, Moniz RD, Klem C, Rosenblatt L, Wu G, Kremer JM (2011) Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 29:494\u2013499","journal-title":"Clin Exp Rheumatol"},{"key":"4173_CR9","first-page":"448","volume":"36","author":"AS Neubauer","year":"2018","unstructured":"Neubauer AS, Minartz C, Herrmann KH, Baerwald C (2018) Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept. Clin Exp Rheumatol 36:448\u2013454","journal-title":"Clin Exp Rheumatol"},{"key":"4173_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603\u20131609","journal-title":"Ann Rheum Dis"},{"key":"4173_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3899\/jrheum.100935","volume":"38","author":"EC Keystone","year":"2011","unstructured":"Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B (2011) Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol 38:990\u2013996","journal-title":"J Rheumatol"},{"key":"4173_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.autrev.2013.01.001","volume":"12","author":"M Cutolo","year":"2013","unstructured":"Cutolo M, Nadler S (2013) Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 12:758\u2013767","journal-title":"Autoimmun Rev"},{"key":"4173_CR13","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3899\/jrheum.140137","volume":"41","author":"B Kuriya","year":"2014","unstructured":"Kuriya B, Xiong J, Boire G, Haraoui B, Hitchon C, Pope J, Thorne JC, Tin D, Keystone EC, Bykerk V (2014) Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis\u2013results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol 41:2161\u20132166","journal-title":"J Rheumatol"},{"key":"4173_CR14","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/rheumatology\/kel358","volume":"45","author":"V Strand","year":"2006","unstructured":"Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, Lehane PB, Agarwal S (2006) Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology 45:1505\u20131513","journal-title":"Rheumatology"},{"issue":"Suppl 11","key":"4173_CR15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/acr.20620","volume":"63","author":"L Maska","year":"2011","unstructured":"Maska L, Anderson J, Michaud K (2011) Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res (Hoboken) 63(Suppl 11):S4\u2013S13","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4173_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/ard.2009.108159","volume":"69","author":"JH Coombs","year":"2010","unstructured":"Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69:413\u2013416","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s00296-018-4232-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000}}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4173-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4173-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T19:26:56Z","timestamp":1600284416000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4173-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4173-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00296-018-4232-9","asserted-by":"object"}]},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"15 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \ufffd\ufffd\ufffdOn-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis\ufffd\ufffd\ufffd, written by Vivian P.Bykerk, was originally published Online First without open access.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \ufffd\ufffd\ufffdOn-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis\ufffd\ufffd\ufffd, written by Vivian P.Bykerk, was originally published Online First without open access.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by local institutional review boards or Independent Ethics Committees at each site (ClinicalTrials.gov; NCT01142726). The laws and regulatory requirements of all countries participating in this study were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}